WINNIPEG, Feb. 3, 2020 /CNW/ - Waverley Pharma Inc.
("Waverley Pharma" or the "Company") (TSXV:WAVE), an emerging
Canadian pharmaceutical company, announced today the
appointment, by the board of directors, of Mr. Larry Thiessen as the new President and Chief
Executive Officer, effective February
1, 2020. Mr. Thiessen has extensive pharmaceutical
experience having worked for Bausch Health Companies Inc. (formerly
Biovail Corporation), for the past 28 years, working his way up
from manager to site director of the manufacturing operation in
Steinbach, Manitoba. He
led a team of roughly 400 employees and provided overall leadership
and strategic direction at the operation. Mr. Thiessen has a
Bachelor of Science in Biology and an Executive M.B.A. from
Athabasca University in
Edmonton, Alberta.
Dr. Albert Friesen, Chairman of
the Company said, "The board is very pleased to welcome Larry to
lead Waverley Pharma into the future. We look forward
to working with him as he brings his extensive knowledge and
leadership experience to the Company."
Waverley Pharma also announced today that it has authorized the
grant of an aggregate of 250,000 stock options (each an "Option")
to certain directors and officers of the Company, including Mr.
Thiessen, in accordance with the Company's stock option plan. Each
Option will be exercisable into one common share of the Company at
the closing market price of the Company's common shares on the date
of grant, for a period of five years from the date of grant. The
issuance of the Options is subject to the approval of the TSX
Venture Exchange.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on
the development and commercialization of safe, effective and
affordable cancer therapeutics in the EU and North American market.
The Company, through its subsidiary, is selling two generic
oncology products in the United
Kingdom, namely capecitabine and temozolomide and has three
additional generic products under development. Waverley Pharma is
committed to providing patients with affordable prescription
medicines that lower healthcare costs and provide a better quality
of life. For more information on Waverley Pharma please visit
www.waverleypharma.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Waverley Pharma Inc.